Business Context and Reporting Period
The supplied filing is Rosewind Corporation’s unaudited Form 10-Q for the quarter ended February 28, 2013, covering the three and six months then ended. This does not match the request metadata naming AYTU Biopharma. Rosewind described itself as a development-stage offshore sailing-school company; a non-binding letter of intent discussed a possible move into drug development through an acquisition of Glycomar Limited.
Financial Results and Liquidity
- Revenue: None in the three- or six-month periods ended February 28, 2013, or the comparable 2012 periods. Revenue since inception was $3,500.
- Net loss: $13,659 for the quarter, versus $10,079; $33,517 for six months, versus $29,746. Six-month loss widened by $3,771, or about 13%. Basic and diluted loss per share was $0.00 for the quarter and $0.01 for six months.
- Expenses and interest: Six-month operating expenses were $31,383, versus $28,099; interest expense was $2,134, versus $1,647. Profit margins are not meaningful given no period revenue.
- Cash flow: Six-month operating cash outflow was $17,197, compared with $19,380 in 2012. Financing provided $20,274, including $15,274 in related-party loan proceeds and $5,000 from stock issuance. Cash increased $3,077 to $3,186.
- Balance sheet and liquidity: At February 28, cash was $3,186, total assets $13,113, current liabilities $107,948, and shareholders’ deficit $94,835. The MD&A reports working capital deficit of $104,762 and cash of $3,187, differing from the balance sheet by $1.
- Debt: Related-party loans payable were $83,327, plus $10,603 accrued interest. The secured note to the sole officer and director bears 6% interest, is payable on demand, and is secured by the sailing vessel.
Material Changes, Outlook, and Risks
- Management attributed the six-month loss increase principally to higher professional fees and interest expense, noting increased auditor fees and a growing related-party loan balance.
- The company warned that cash was insufficient to sustain operations and disclosed substantial doubt about its ability to continue as a going concern. It intended to seek additional equity funding, with no assurance of success.
- On January 11, 2013, Rosewind signed a non-binding letter of intent with Glycomar Limited. The proposal contemplated raising $3 million to fund Glycomar’s drug-development program and issuing 20 million Rosewind shares to acquire all of Glycomar. The filing does not establish that the financing or acquisition was completed.
- Key disclosed risks included limited revenue and student bookings, ongoing losses, dependence on additional funding, public-company costs, possible regulatory or licensing requirements, under-insurance, operational hazards, and reliance on a sole officer/director. Management provided no quantified financial guidance.
- The filing states disclosure controls were effective and reports no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Confirm the issuer and filing: the supplied text identifies Rosewind Corporation, not AYTU Biopharma; its contents page also refers to financial statements for a period ended November 30, 2012, while the statements and cover identify February 28, 2013.
- Verify whether the Glycomar letter of intent advanced, whether the proposed $3 million financing was obtained, and whether any share issuance or acquisition occurred.
- Reconcile the $1 difference between reported cash in the balance sheet and MD&A, and confirm current liquidity and obligations under the demand loan.
- Assess the going-concern warning, prospects for financing, and the status of vessel insurance, operating permissions, and student revenue.